A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators

BACKGROUND: While the advent of cystic fibrosis transmembrane conductance regulator (CFTR) modulator use has improved daily life and long‐term prognosis of CF for many with approved CFTR mutations, approximately 10% of people with CF (pwCF) have only symptomatic treatments available. METHODS: Betwee...

Descripción completa

Detalles Bibliográficos
Autores principales: Kramer‐Golinkoff, Emily, Camacho, Amanda, Kramer, Liza, Taylor‐Cousar, Jennifer L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314897/
https://www.ncbi.nlm.nih.gov/pubmed/35170259
http://dx.doi.org/10.1002/ppul.25859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314897/
https://www.ncbi.nlm.nih.gov/pubmed/35170259
http://dx.doi.org/10.1002/ppul.25859

Ejemplares similares